目的：本研究探讨胰腺癌hENT-1表达水平对吉西他滨辅助化疗的影响。方法：利用胰腺癌组织切片，行hENT-1 免疫组织化学实验，针对其染色强度、范围计算评分。追踪回访对应患者的预后情况后行统计学分析。结果：hENT-1高表达组与低表达组的OS为20个月对10个月，而DFS为15个月对6个月。OS的独立预后因素是hENT-1表达水平、淋巴转移情况和病理分级。而DFS的独立预后因素是hENT-1表达水平和病理分级。病人之间临床资料与hENT-1表达水平无明显差异（p＞0.05）。结论：胰腺癌细胞中hENT-1的表达水平可能影响吉西他滨辅助化疗敏感性，hENT-1高表达者使用吉西他滨辅助化疗后的OS及DFS较低表达者长。

Objective: The aim of this study was to investigate the effect of hENT-1 expression on gemcitabine adjuvant chemotherapy in pancreatic cancer.Methods:hENT-1 immunohistochemistry was used to detect pancreatic cancer tissue sections. The score was calculated according to the dyeing intensity and range of hENT-1. The prognosis of the corresponding patients was followed up and statistically analyzed.Results: The OS of high expression group and low expression group was 20 months vs 10 months. DFS was 15 months vs 6 months. The independent prognostic factors of overall survival were the expression level of hENT-1, lymphatic metastasis and pathological grade. The independent prognostic factors of disease free survival were hENT-1 expression level and pathological grade. There was no significant difference in clinical data and expression level of hENT-1 between patients (P > 0.05). Conclusion: The hENT-1 expression may affect the sensitivity of gemcitabine to adjuvant chemotherapy. And the OS and DFS of patients with high expression of hENT-1 after gemcitabine adjuvant chemotherapy were longer than those with low expression.

内蒙古自然科学基金（2019MS08013）